Result of AGM

Oxford, UK - 06 June 2013: Oxford BioMedica ("the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, announced today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held today in London.

In accordance with Listing Rule 9.6.18, the following resolutions are those which were passed at the meeting concerning special business:

· Resolution 8: to empower the Directors to allot equity securities for cash, pursuant to section 570 of the Act as if section 561 of the Act did not apply to such allotment, up to an aggregate nominal amount representing 5 per cent of presently issued shares; and

· Resolution 9: to permit the Company to convene general meetings (other than annual general meetings) by not less than 14 days' notice.

The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Company's website at www.oxfordbiomedica.co.uk.

Certified copies of the document setting out the above resolutions passed at the 2013 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.Hemscott.com/nsm.do.

The results of the proxy voting in advance of the meeting are shown below. On the Record Date (4 June 2013) there were 1,416,149,005 1p ordinary shares in issue, each carrying one vote per share.

Resolution

Votes

For

Votes at

Chairman's

Discretion

Votes at

other proxy

Discretion

Votes

Against

Votes

Withheld

Total

votes cast

Result

Ordinary resolutions

1

798,015,210

718,720

3,930,170

98,838

836,022

803,598,960

Passed

2

797,418,859

719,921

3,930,170

553,064

891,828

803,513,842

Passed

3

797,776,116

719,067

3,930,170

234,065

866,983

803,526,401

Passed

4

797,854,651

721,377

3,930,170

152,287

867,916

803,526,401

Passed

5

797,585,441

722,136

3,930,170

394,241

834,413

803,466,401

Passed

6

797,028,458

784,413

3,930,170

951,823

904,096

803,598,960

Passed

7

796,847,889

760,464

3,930,170

1,029,913

957,965

803,526,401

Passed

Special resolutions

8

796,765,637

761,352

3,930,170

1,050,445

958,797

803,466,401

Passed

9

796,884,579

786,797

3,930,170

1,095,721

816,575

803,513,842

Passed

A copy of the slides presented at the AGM will be available on the Company's website after the meeting. No new material information will be revealed at the meeting.

-Ends-

For further information, please contact:

Oxford BioMedica plc:

Lara Mott, Head of Corporate Communications

Tel: +44 (0)1865 783 000

Media Enquiries:

Mary-Jane Elliott/Sarah Macleod/Claire Dickinson M:Communications

Tel: +44 (0)20 7920 2360

Notes to editors

1. Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.